Clene NASDAQ: CLNN is preparing to submit a New Drug Application, or NDA, seeking accelerated approv

MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth. com a leading independent small cap media p

SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that man

Clene Inc. (CLNN) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estima

Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pa

Clene NASDAQ: CLNN said it is preparing to submit a new drug application, or NDA, in early fourth qu

SALT LAKE CITY, July 29, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidia

Clene (CLNN) appears to have found support after losing some value lately, as indicated by the forma

Clene Inc. (CLNN) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estim

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.69) per share which missed the analyst consensu

After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8 ® unde

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiar

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiar

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and ma

Clene Inc. (NASDAQ:CLNN) shares are up 6.68% on Monday as the company is filing for accelerated appr

FDA signals accelerated pathway for Clene's ALS drug CNM-Au8, with NDA filing planned and mixed

Mirum stock rises after Phase 2b VISTAS data for volixibat; AZURE-1 results and technical levels hig

Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidi

FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 7,748 shares of

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 6,374 shares of

Clene Inc. (NASDAQ: CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 25,040 shares of

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.88) per share which missed the analyst consensu

In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM

SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidia

Ventyx Biosciences (NASDAQ: VTYX - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are b

The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent ana

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") an

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene" or the "Company") an

Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidi

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.85) per share which missed the analyst consensu

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ: CLNN) with a Buy and maintains $2

Benchmark analyst Bruce D. Jackson maintains Clene (NASDAQ:CLNN) with a Buy and lowers the price

Novel human preclinical neuronal model for Parkinson's disease demonstrated CNM-Au8's abilit

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23

Canaccord Genuity analyst Sumant Kulkarni maintains Clene (NASDAQ:CLNN) with a Buy and lowers the

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23

Clene (NASDAQ:CLNN) reported quarterly losses of $(0.78) per share which missed the analyst consensu

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23

D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23